Robert Coffin
Fondateur chez REPLIMUNE GROUP, INC.
Fortune : 16 M $ au 30/06/2024
Profil
Robert Coffin was the founder of BioVex, Inc. (founded in 1999) where he held the title of Chief Technology Officer in 2009.
He is also the founder of Replimune Group, Inc. (founded in 2015) where he currently holds the title of Director & Chief Scientist.
Additionally, he was the founder of BioVex Group, Inc. (founded in 1999) where he held the title of Director & Chief Technology Officer from 2009 to 2011.
Dr. Coffin's former job includes working at BioVex Ltd.
(1999-2011) as Director & Chief Technology Officer.
He also worked at Amgen, Inc. (2011-2013) as Vice President-Global Development.
Dr. Coffin obtained a doctorate degree from Imperial College London in 1991.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
2,97% | 16/05/2024 | 1 821 872 ( 2,97% ) | 16 M $ | 30/06/2024 |
Postes actifs de Robert Coffin
| Sociétés | Poste | Début |
|---|---|---|
| REPLIMUNE GROUP, INC. | Fondateur | 01/03/2015 |
Anciens postes connus de Robert Coffin
| Sociétés | Poste | Fin |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 01/01/2013 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | 04/03/2011 |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Fondateur | 01/01/2011 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Fondateur | - |
Formation de Robert Coffin
| Imperial College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REPLIMUNE GROUP, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
